GoAI
Get started
Cryo-Cell International, Inc. logo

Cryo-Cell International, Inc.

CCEL

AMEXHealthcareMedical - Care Facilities

Open in GoAI

Previous close

$4.56

+$0.38 · +9.09%

Aug 21, 4:00 PM ET

CCEL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

27

Expensive

Momentum

30

Weakening

Sentiment

40

Bearish

Risk resilience

36

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
US
CEO
David Portnoy
Listed since
Apr 4, 1994
Employees
74

Market position

Day range

Current $4.56

52-week range

Current $4.56

Open
$4.26
Previous close
$4.18
Volume
51.34K
2.89× average
Average volume
17.75K
Average daily volume
Market cap
36.77M USD
Beta
0.52
Market reference 1
50-day average
$3.59
+27.02% above average
200-day average
$3.5735
+27.61% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
43.35M USD
P/E (TTM)
-15.5×
P/B (TTM)
-2.07×
P/S (TTM)
1.18×
EV / EBITDA
39.51×
Earnings yield
-7.56%
Free cash flow yield
16.34%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
77.34%
Operating margin
-0.33%
Net margin
-7.92%
Return on equity
13.06%
Return on assets
-3.94%
Return on invested capital
10.79%

Financial health

Debt / equity
-0.5×
Current ratio
0.59×
Altman Z-score
-0.2
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends88%42%-4%-51%Gross margin, FY2021: 68.88%Gross margin, FY2022: 71.02%Gross margin, FY2023: 73.07%Gross margin, FY2024: 75.15%Gross margin, FY2025: 76.63%Operating margin, FY2021: 13.91%Operating margin, FY2022: 13.27%Operating margin, FY2023: -39.26%Operating margin, FY2024: 10.88%Operating margin, FY2025: 15.34%Net margin, FY2021: 7.21%Net margin, FY2022: 9.14%Net margin, FY2023: -30.38%Net margin, FY2024: 1.26%Net margin, FY2025: -7.70%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 68.88%. Gross margin FY2022 71.02%. Gross margin FY2023 73.07%. Gross margin FY2024 75.15%. Gross margin FY2025 76.63%. Operating margin FY2021 13.91%. Operating margin FY2022 13.27%. Operating margin FY2023 -39.26%. Operating margin FY2024 10.88%. Operating margin FY2025 15.34%. Net margin FY2021 7.21%. Net margin FY2022 9.14%. Net margin FY2023 -30.38%. Net margin FY2024 1.26%. Net margin FY2025 -7.70%.

Income trends

Revenue

31.57M USD-1.31%

Operating income

4.84M USD+39.10%

Net income

−2.43M USD−2.83M USD
Income trends across reported periods36.42M USD18.7M USD983.01K USD−16.73M USDRevenue, FY2021: 28.88M USDRevenue, FY2022: 30.34M USDRevenue, FY2023: 31.34M USDRevenue, FY2024: 31.99M USDRevenue, FY2025: 31.57M USDOperating income, FY2021: 4.02M USDOperating income, FY2022: 4.02M USDOperating income, FY2023: −12.3M USDOperating income, FY2024: 3.48M USDOperating income, FY2025: 4.84M USDNet income, FY2021: 2.08M USDNet income, FY2022: 2.77M USDNet income, FY2023: −9.52M USDNet income, FY2024: 402.1K USDNet income, FY2025: −2.43M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 28.88M USD. Revenue FY2022 30.34M USD. Revenue FY2023 31.34M USD. Revenue FY2024 31.99M USD. Revenue FY2025 31.57M USD. Operating income FY2021 4.02M USD. Operating income FY2022 4.02M USD. Operating income FY2023 −12.3M USD. Operating income FY2024 3.48M USD. Operating income FY2025 4.84M USD. Net income FY2021 2.08M USD. Net income FY2022 2.77M USD. Net income FY2023 −9.52M USD. Net income FY2024 402.1K USD. Net income FY2025 −2.43M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue31.57M USD31.99M USD31.34M USD30.34M USD28.88M USD
Cost of goods sold7.38M USD7.95M USD8.44M USD8.79M USD8.99M USD
Gross profit24.19M USD24.04M USD22.9M USD21.54M USD19.9M USD
Research and development376.26K USD1.24M USD1.17M USD384.79K USD49.87K USD
Selling, general, and administrative18.22M USD18.52M USD17.12M USD15.58M USD14.63M USD
Operating expenses19.35M USD20.56M USD35.21M USD17.52M USD15.88M USD
Interest expense2.07M USD1.86M USD1.24M USD1.52M USD1.38M USD
Depreciation and amortization1.37M USD483.52K USD1.71M USD1.81M USD1.33M USD
Operating income4.84M USD3.48M USD−12.3M USD4.02M USD4.02M USD
Net income−2.43M USD402.1K USD−9.52M USD2.77M USD2.08M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.3
FY2025 · -700.00% year over year
Latest fiscal-year revenue
31.57M USD
FY2025 · -1.31% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend0.48-0.11-0.7-1.29FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend32.3M31.06M29.82M28.57MFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$8.50

86.40% upside
Past 12 months12-month forecastHigh $8.50Average $8.50Low $8.50

Recent analyst actions

1 institution

Corporate actions

Corporate action history

Dividend

Ex-dividend May 21, 2025

$0.15

Quarterly

Record May 21, 2025 · Payment May 30, 2025

Dividend

Ex-dividend Feb 14, 2025

$0.25

Quarterly

Record Feb 14, 2025 · Payment Feb 28, 2025

Dividend

Ex-dividend Nov 15, 2024

$0.25

Annual

Record Nov 15, 2024 · Payment Nov 29, 2024

Dividend

Ex-dividend Sep 1, 2022

$0.90

Special

Record Sep 2, 2022 · Payment Sep 9, 2022

CCEL peers

National HealthCare Corporation logo

NHC

National HealthCare Corporation

$233.4

-1.41%

Perspective Therapeutics, Inc. logo

CATX

Perspective Therapeutics, Inc.

$3.30

+2.80%

Electromed, Inc. logo

ELMD

Electromed, Inc.

$39.45

-1.38%

Lineage Cell Therapeutics, Inc. logo

LCTX

Lineage Cell Therapeutics, Inc.

$1.08

0.00%

InfuSystem Holdings, Inc. logo

INFU

InfuSystem Holdings, Inc.

$12.21

+0.08%

Protalix BioTherapeutics, Inc. logo

PLX

Protalix BioTherapeutics, Inc.

$2.38

0.00%

ETFs holding CCEL

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
323.83K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
154.97K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research CCEL

research.disclaimer